JP2006505587A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006505587A5 JP2006505587A5 JP2004546863A JP2004546863A JP2006505587A5 JP 2006505587 A5 JP2006505587 A5 JP 2006505587A5 JP 2004546863 A JP2004546863 A JP 2004546863A JP 2004546863 A JP2004546863 A JP 2004546863A JP 2006505587 A5 JP2006505587 A5 JP 2006505587A5
- Authority
- JP
- Japan
- Prior art keywords
- hydroalcoholic gel
- therapeutic agent
- phosphodiesterase inhibitor
- gel
- type phosphodiesterase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 7
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims 4
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims 4
- 229940079593 drugs Drugs 0.000 claims 3
- 229960002639 Sildenafil citrate Drugs 0.000 claims 2
- 229960003604 Testosterone Drugs 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 230000035936 sexual power Effects 0.000 claims 2
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- AXISYYRBXTVTFY-UHFFFAOYSA-N Isopropyl myristate Chemical compound CCCCCCCCCCCCCC(=O)OC(C)C AXISYYRBXTVTFY-UHFFFAOYSA-N 0.000 claims 1
- 210000003491 Skin Anatomy 0.000 claims 1
- 230000001476 alcoholic Effects 0.000 claims 1
- 150000001298 alcohols Chemical class 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229940074928 isopropyl myristate Drugs 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 239000003961 penetration enhancing agent Substances 0.000 claims 1
- 229920001888 polyacrylic acid Polymers 0.000 claims 1
- 239000004584 polyacrylic acid Substances 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 230000002194 synthesizing Effects 0.000 claims 1
- 239000002562 thickening agent Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Claims (6)
- 雄性対象における性的遂行能力の治療に役立つ薬剤の効率を向上させるための水性アルコール性ゲルであって、
前記ゲルは、テストステロン合成経路中のステロイド、1種以上のC1〜C4アルコール、透過促進剤、増粘剤および水を含有し、
前記薬剤が、V型ホスホジエステラーゼ阻害薬であることを特徴とする水性アルコール性ゲル。 - 重量基準で、
(a)テストステロン0.1%から10%、
(b)ミリスチン酸イソプロピル0.1%から5%、
(c)ポリアクリル酸0.1%から5%、および
(d)エタノール30%から約98%
を含有する請求項1記載の水性アルコール性ゲル。 - 前記薬剤が、クエン酸シルデナフィル、その塩またはその鏡像異性体であることを特徴とする請求項1または2記載の水性アルコール性ゲル。
- 雄性対象における性的遂行能力の治療薬であって、
請求項1〜3のいずれかに記載の水性アルコール性ゲルと、V型ホスホジエステラーゼ阻害薬との組み合わせを含み、
前記水性アルコール性ゲルが、前記対象の皮膚に投与される治療薬。 - 前記水性アルコール性ゲルと、前記V型ホスホジエステラーゼ阻害薬を含む薬剤とを含むキットとして提供される請求項4記載の治療薬。
- 前記V型ホスホジエステラーゼ阻害薬が、クエン酸シルデナフィル、その塩またはその鏡像異性体であることを特徴とする請求項4または5記載の治療薬。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/273,484 US20030139384A1 (en) | 2000-08-30 | 2002-10-18 | Method for treating erectile dysfunction and increasing libido in men |
PCT/US2003/032597 WO2004037173A2 (en) | 2002-10-18 | 2003-10-16 | Method for treating erectile dysfunction and increasing libido in men |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2006505587A JP2006505587A (ja) | 2006-02-16 |
JP2006505587A5 true JP2006505587A5 (ja) | 2006-11-30 |
Family
ID=32174519
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004546863A Pending JP2006505587A (ja) | 2002-10-18 | 2003-10-16 | 男性における勃起機能不全を治療し、性欲を増進する方法 |
Country Status (7)
Country | Link |
---|---|
US (3) | US20030139384A1 (ja) |
EP (1) | EP1551416A4 (ja) |
JP (1) | JP2006505587A (ja) |
AU (1) | AU2003277388A1 (ja) |
CA (1) | CA2502607A1 (ja) |
MX (1) | MXPA05004093A (ja) |
WO (1) | WO2004037173A2 (ja) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPN814496A0 (en) * | 1996-02-19 | 1996-03-14 | Monash University | Dermal penetration enhancer |
US7235625B2 (en) * | 1999-06-29 | 2007-06-26 | Palatin Technologies, Inc. | Multiple agent therapy for sexual dysfunction |
US20070225379A1 (en) * | 2001-08-03 | 2007-09-27 | Carrara Dario Norberto R | Transdermal delivery of systemically active central nervous system drugs |
US7198801B2 (en) * | 2000-08-03 | 2007-04-03 | Antares Pharma Ipl Ag | Formulations for transdermal or transmucosal application |
US20040198706A1 (en) * | 2003-03-11 | 2004-10-07 | Carrara Dario Norberto R. | Methods and formulations for transdermal or transmucosal application of active agents |
US8980290B2 (en) | 2000-08-03 | 2015-03-17 | Antares Pharma Ipl Ag | Transdermal compositions for anticholinergic agents |
US20040092494A9 (en) * | 2000-08-30 | 2004-05-13 | Dudley Robert E. | Method of increasing testosterone and related steroid concentrations in women |
US20040002482A1 (en) * | 2000-08-30 | 2004-01-01 | Dudley Robert E. | Androgen pharmaceutical composition and method for treating depression |
US6503894B1 (en) | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
MY139721A (en) * | 2002-04-19 | 2009-10-30 | Cpex Pharmaceuticals Inc | Pharmaceutical composition |
KR20050045946A (ko) | 2002-06-25 | 2005-05-17 | 애크럭스 디디에스 피티와이 리미티드 | 비정질 약학적 조성물을 이용한 경피전달속도의 제어 |
US20040259852A1 (en) * | 2003-06-18 | 2004-12-23 | White Hillary D. | Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome |
US8883769B2 (en) * | 2003-06-18 | 2014-11-11 | White Mountain Pharma, Inc. | Methods for the treatment of fibromyalgia and chronic fatigue syndrome |
BRPI0414551B8 (pt) | 2003-10-10 | 2021-05-25 | Antares Pharma Ipl Ag | formulação farmacêutica transdérmica ou transmucosa e método de protelação ou inibição da cristalização de um agente ativo |
PT1530965E (pt) | 2003-11-11 | 2006-05-31 | Udo Mattern | Sistema de administracao de libertacao controlada de hormonas sexuais para aplicacao nasal |
US8784869B2 (en) | 2003-11-11 | 2014-07-22 | Mattern Pharma Ag | Controlled release delivery system for nasal applications and methods of treatment |
US7425340B2 (en) * | 2004-05-07 | 2008-09-16 | Antares Pharma Ipl Ag | Permeation enhancing compositions for anticholinergic agents |
KR101292492B1 (ko) | 2004-05-11 | 2013-08-01 | 이모셔널 브레인 비.브이. | 약제학적 제형물 및 여성 성기능 부전의 치료에서 그것의용도 |
EP1634583A1 (en) * | 2004-09-09 | 2006-03-15 | Laboratoires Besins International | Testosterone gels comprising propylene glycol as penetration enhancer |
JP2008534505A (ja) * | 2005-03-25 | 2008-08-28 | メルク エンド カムパニー インコーポレーテッド | テストステロンサプリメントおよび5アルファ−レダクターゼインヒビターによる男性の治療方法 |
US20070088012A1 (en) * | 2005-04-08 | 2007-04-19 | Woun Seo | Method of treating or preventing type-2 diabetes |
WO2006125642A1 (en) * | 2005-05-27 | 2006-11-30 | Antares Pharma Ipl Ag | Methods and apparatus for transdermal or transmucosal application of testosterone |
AU2006254742C1 (en) * | 2005-06-03 | 2011-11-03 | Acrux Dds Pty Ltd | Method and composition for transdermal drug delivery |
MX2007015255A (es) * | 2005-06-03 | 2008-02-22 | Acrux Dds Pty Ltd | Metodo y composicion para administracion transdermica de un farmaco. |
NZ563946A (en) * | 2005-06-03 | 2012-02-24 | Acrux Dds Pty Ltd | Testosterone containing non-occlusive transdermal drug delivery composition for application to the arm pit / axilla |
GEP20125432B (en) * | 2005-10-12 | 2012-03-26 | Unimed Pharmaceuticals Llc | Improved testosterone gel and use thereof |
EP1790343A1 (en) | 2005-11-11 | 2007-05-30 | Emotional Brain B.V. | Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction |
CN101426475A (zh) | 2006-04-21 | 2009-05-06 | 安塔雷斯制药Ipl股份公司 | 使用用于经皮或经粘膜应用的制剂治疗热潮红的方法 |
PT2068825E (pt) | 2006-10-04 | 2011-02-11 | M & P Patent Ag | Sistema de administração de libertação controlada para aplicação nasal de neurotransmissores |
EP1925307A1 (en) | 2006-11-03 | 2008-05-28 | Emotional Brain B.V. | Use of 3-alpha-androstanediol in the treatment of sexual dysfunction |
WO2008067991A2 (en) * | 2006-12-08 | 2008-06-12 | Antares Pharma Ipl Ag | Skin-friendly drug complexes for transdermal administration |
MX2009008995A (es) * | 2007-03-23 | 2009-09-03 | Unimed Pharmaceuticals Llc | Composiciones y metodos para tratar hipogonadismo pediatrico. |
DE102007028869A1 (de) * | 2007-06-22 | 2008-12-24 | Ratiopharm Gmbh | Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil |
CN102196821A (zh) * | 2008-10-31 | 2011-09-21 | 莫贝里德尔马公司 | 包含至少两种渗透增强剂组合的局部组合物 |
JP2010163425A (ja) * | 2008-12-18 | 2010-07-29 | Daiichi Sankyo Healthcare Co Ltd | ホスホジエステラーゼ5阻害剤とパンテチンを含有する医薬組成物 |
DE102009033396A1 (de) | 2009-07-16 | 2011-01-20 | Ratiopharm Gmbh | Wässrige Lösung und gelatinierte Zusammensetzung umfassend einen Phosphodiesterase-5-Inhibitor sowie diesbezügliche Verfahren und Verwendung |
DE102009035211A1 (de) | 2009-07-29 | 2011-02-17 | Ratiopharm Gmbh | Copräzipitate umfassend einen Phosphodiesterase-5-Inhibitor (PDE-5-Inhibitor) und einen pharmazeutisch verträglichen Trägerstoff, ihre Herstellung und Verwendung |
EP2640398A4 (en) | 2010-11-18 | 2014-05-14 | White Mountain Pharma Inc | METHODS FOR TREATING CHRONIC OR REFRACTORY PAIN AND / OR INCREASING PAIN THRESHOLD IN A SUBJECT, AND ASSOCIATED PHARMACEUTICAL COMPOSITIONS |
TWI422399B (zh) * | 2011-01-21 | 2014-01-11 | Tritech Biopharmaceuticals Co Ltd | 促進第五型磷酸二酯酶抑制劑經皮吸收的醫藥組成物 |
JO3755B1 (ar) * | 2011-01-26 | 2021-01-31 | Ferring Bv | تركيبات تستوستيرون |
US20130045958A1 (en) | 2011-05-13 | 2013-02-21 | Trimel Pharmaceuticals Corporation | Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder |
US20130040923A1 (en) | 2011-05-13 | 2013-02-14 | Trimel Pharmaceuticals Corporation | Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder |
US9757388B2 (en) | 2011-05-13 | 2017-09-12 | Acerus Pharmaceuticals Srl | Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels |
HUE041292T2 (hu) * | 2011-12-26 | 2019-05-28 | Tritech Biopharmaceuticals Co Ltd | Eljárás és feljavított gyógyszerészeti kompozíció PDE-5 inhibitor transzdermális átvitelének erõsítésére |
US20150290217A1 (en) * | 2012-11-21 | 2015-10-15 | Trimel Biopharma Srl | Male testosterone titration methods, male intranasal testosterone bio-adhesive gel formulations and use thereof for treating hypogonadism and trt |
WO2014080282A2 (en) * | 2012-11-22 | 2014-05-30 | Trimel Biopharma Srl | One-and two-point titration methods to determine daily treatment regimens to treat hypogonadism or male testosterone deficiency with an intranasal testosterone bio-adhesive gel, and primary and secondary efficacy and safety endpoints |
CA2904293A1 (en) | 2013-03-04 | 2014-09-12 | Function Promoting Therapies, Llc | Methods and systems for the diagnosis and treatment of androgen disorders |
US11744838B2 (en) | 2013-03-15 | 2023-09-05 | Acerus Biopharma Inc. | Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event |
US10213440B2 (en) * | 2014-08-20 | 2019-02-26 | Professional Compounding Centers Of America (Pcca) | Oral transmucosal pharmaceutical compositions including testosterone and an aromatase inhibitor |
ES2864099T3 (es) * | 2015-04-03 | 2021-10-13 | Benuvia Therapeutics Llc | Formulaciones de pulverización sublingual de sildenafilo |
US20170014417A1 (en) | 2015-07-14 | 2017-01-19 | Lipp Life Sciences Llc | Pharmaceutical administration system for the transdermal application of vardenafil |
CA2994709A1 (en) * | 2015-08-03 | 2017-02-09 | Synergistic Therapeutics, Llc | Sexual dysfunction therapeutic gel |
KR20180074707A (ko) * | 2015-10-15 | 2018-07-03 | 모세 로고스니츠키 | 저 용량 경구 디피리다몰 조성물 및 이의 용도 |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4078060A (en) * | 1976-05-10 | 1978-03-07 | Richardson-Merrell Inc. | Method of inducing an estrogenic response |
US4861764A (en) * | 1986-11-17 | 1989-08-29 | Macro Chem. Corp. | Percutaneous absorption enhancers, compositions containing same and method of use |
US4855305A (en) * | 1987-03-23 | 1989-08-08 | Applied Medical Research | Compositions and methods of effecting contraception utilizing melatonin |
US5231087A (en) * | 1988-03-16 | 1993-07-27 | Cellegy Pharmaceuticals, Inc. | Treatment of skin diseases and tumors with esters and amides of monocarboxylic acids |
JP3238389B2 (ja) * | 1988-10-27 | 2001-12-10 | シエーリング アクチエンゲゼルシヤフト | ゲストデン含有の経皮適用のための薬剤 |
WO1990010462A1 (en) * | 1989-03-10 | 1990-09-20 | Endorecherche Inc. | Combination therapy for treatment of estrogen sensitive diseases |
US5788983A (en) * | 1989-04-03 | 1998-08-04 | Rutgers, The State University Of New Jersey | Transdermal controlled delivery of pharmaceuticals at variable dosage rates and processes |
US5152997A (en) * | 1990-12-11 | 1992-10-06 | Theratech, Inc. | Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels |
NZ253409A (en) * | 1992-06-11 | 1996-09-25 | Theratech Inc | Drug delivery system; transdermal/transmucosal system using glycerine to moderate drug delivery |
BR9306564A (pt) * | 1992-06-19 | 1999-01-12 | Univ California | Processo para o tratamento da epiderme de um mamífero terrestre sofrendo de uma condição constitída por uma função de barreira epidérmica perturbada |
DE4223004A1 (de) * | 1992-07-13 | 1994-01-20 | Liedtke Pharmed Gmbh | Einzeldosierte halbfeste topische Arzneiform zur Transdermaltherapie |
US5885565A (en) * | 1993-03-19 | 1999-03-23 | Cellegy Pharmaceuticals Inc. | Methods for inducing phase separation of epithelial lipid bilayers |
US5698589A (en) * | 1993-06-01 | 1997-12-16 | International Medical Innovations, Inc. | Water-based topical cream containing nitroglycerin and method of preparation and use thereof |
NZ293849A (en) * | 1994-09-14 | 1998-10-28 | Minnesota Mining & Mfg | Transdermal delivery matrix comprising a macromonomer containing acrylate or metacrylate copolymer, a softener and a drug |
US5730987A (en) * | 1996-06-10 | 1998-03-24 | Omar; Lotfy Ismail | Medication for impotence containing lyophilized roe and a powdered extract of Ginkgo biloba |
US5760096A (en) * | 1996-10-18 | 1998-06-02 | Thornfeldt; Carl R. | Potent penetration enhancers |
CN1231592A (zh) * | 1996-10-30 | 1999-10-13 | 瑟垃技术有限公司 | 作为渗透促进剂的羟乙酸及其盐的脂肪酸酯 |
US6019997A (en) * | 1997-01-09 | 2000-02-01 | Minnesota Mining And Manufacturing | Hydroalcoholic compositions for transdermal penetration of pharmaceutical agents |
US5968919A (en) * | 1997-10-16 | 1999-10-19 | Macrochem Corporation | Hormone replacement therapy drug formulations for topical application to the skin |
US6319913B1 (en) * | 1997-11-10 | 2001-11-20 | Cellegy Pharmaceuticals, Inc. | Penetration enhancing and irritation reducing systems |
US5942545A (en) * | 1998-06-15 | 1999-08-24 | Macrochem Corporation | Composition and method for treating penile erectile dysfunction |
US6200591B1 (en) * | 1998-06-25 | 2001-03-13 | Anwar A. Hussain | Method of administration of sildenafil to produce instantaneous response for the treatment of erectile dysfunction |
DE19903087A1 (de) * | 1999-01-27 | 2000-08-10 | Forssmann Wolf Georg | Behandlung von erektilen Dysfunktionen mit C-Typ Natriuretischem Polypeptid (CNP) als Monotherapie oder in Kombination mit Phosphodiesterasehemmern |
US6087362A (en) * | 1999-03-16 | 2000-07-11 | Pentech Pharmaceuticals, Inc. | Apomorphine and sildenafil composition |
US6586000B2 (en) * | 1999-12-16 | 2003-07-01 | Dermatrends, Inc. | Hydroxide-releasing agents as skin permeation enhancers |
US6562370B2 (en) * | 1999-12-16 | 2003-05-13 | Dermatrends, Inc. | Transdermal administration of steroid drugs using hydroxide-releasing agents as permeation enhancers |
US6562369B2 (en) * | 1999-12-16 | 2003-05-13 | Dermatrends, Inc. | Transdermal administration of androgenic drugs hydroxide-releasing agents as permeation enhancers |
US6503894B1 (en) * | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
WO2002017927A1 (en) * | 2000-08-30 | 2002-03-07 | Unimed Pharmaceuticals, Inc. | Method for treating erectile dysfunction and increasing libido in men |
US20040092494A9 (en) * | 2000-08-30 | 2004-05-13 | Dudley Robert E. | Method of increasing testosterone and related steroid concentrations in women |
US20030027804A1 (en) * | 2001-06-27 | 2003-02-06 | Van Der Hoop Roland Gerritsen | Therapeutic combinations for the treatment of hormone deficiencies |
US20040072810A1 (en) * | 2001-11-07 | 2004-04-15 | Besins International Belgique | Pharmaceutical composition in the form of a gel or a solution based on dihydrotestosterone, process for preparing it and uses thereof |
US20060088579A1 (en) * | 2002-02-07 | 2006-04-27 | Shastri Venkatram P | Transdermal drug delivery systems |
MY139721A (en) * | 2002-04-19 | 2009-10-30 | Cpex Pharmaceuticals Inc | Pharmaceutical composition |
FR2848112B1 (fr) * | 2002-12-10 | 2007-02-16 | Besins Int Belgique | Composition pharmaceutique pour administration transdermique ou transmuqueuse comprenant au moins un progestatif et/ou au moins un oestrogene, son procede de preparation et ses utilisations |
US20050020552A1 (en) * | 2003-07-16 | 2005-01-27 | Chaim Aschkenasy | Pharmaceutical composition and method for transdermal drug delivery |
US20070082039A1 (en) * | 2004-10-18 | 2007-04-12 | Jones Gerald S Jr | Synthesis of fatty alcohol esters of alpha-hydroxy carboxylic acids, the use of the same as percutaneous permeation enhancers, and topical gels for the transdermal delivery of steroids |
US20070065494A1 (en) * | 2005-08-03 | 2007-03-22 | Watson Laboratories, Inc. | Formulations and Methods for Enhancing the Transdermal Penetration of a Drug |
-
2002
- 2002-10-18 US US10/273,484 patent/US20030139384A1/en not_active Abandoned
-
2003
- 2003-10-16 EP EP03809561A patent/EP1551416A4/en not_active Withdrawn
- 2003-10-16 CA CA002502607A patent/CA2502607A1/en not_active Abandoned
- 2003-10-16 JP JP2004546863A patent/JP2006505587A/ja active Pending
- 2003-10-16 AU AU2003277388A patent/AU2003277388A1/en not_active Abandoned
- 2003-10-16 US US10/531,526 patent/US20060211664A1/en not_active Abandoned
- 2003-10-16 WO PCT/US2003/032597 patent/WO2004037173A2/en active Application Filing
- 2003-10-16 MX MXPA05004093A patent/MXPA05004093A/es active IP Right Grant
-
2004
- 2004-06-14 US US10/867,435 patent/US20050049233A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2006505587A5 (ja) | ||
JP2004524267A5 (ja) | ||
JP2017057230A5 (ja) | ||
JP2007538008A5 (ja) | ||
JP2005512995A5 (ja) | ||
JP2005515964A5 (ja) | ||
JP2005503322A5 (ja) | ||
JP2004538303A5 (ja) | ||
JP2004506682A5 (ja) | ||
JP2006514949A5 (ja) | ||
JP2008514557A5 (ja) | ||
JP2002537232A5 (ja) | ||
HUP0104652A2 (hu) | Nátrium/hidrogén-csere inhibitorok alkalmazása öregkori szervi rendellenességek és öregkori betegségek megakadályozására és az élet meghosszabbítására alkalmas gyógyszerkészítmények előállítására | |
NO20052562L (no) | Anvendelse av distrontiumsalter av 2-[N,N-di(karboksylmetyl)amino]-3-cyano-4-karboksylmetyl-tiofen-5-karboksylsyre for fremstilling av medikamenter for behandlingen av gastro-duodenal smerte. | |
JP2005047851A5 (ja) | ||
JP2008540603A5 (ja) | ||
JP2005513105A5 (ja) | ||
US20100190810A1 (en) | Composition and method for treatment of warts | |
EP4364738A3 (en) | Osmotic dosage forms comprising deutetrabenazine and methods of use thereof | |
US20060287364A1 (en) | Methods of prevention of infection with HIV/AIDS, venereal disease and influenza | |
CA2515259A1 (en) | Use of acetylsalicylic acid for the treatment of hemorrhoidal disease | |
HUP0303754A2 (hu) | Gyökfogó vegyületek alkalmazása NO-függő mikrokeringési zavarok kezelésére és megelőzésére szolgáló gyógyszerkészítmény előállítására | |
JP2006515607A5 (ja) | ||
JP2004520279A5 (ja) | ||
JP2003267863A5 (ja) |